Injectable NAD+: The Science Behind the Shot

BIO PRECISION AGING  |  LONGEVITY SCIENCE SERIES

What it is, how it differs from peptides, what the peer-reviewed evidence actually shows — and why high performers are paying attention.

The Molecule at the Center of How You Age

If there is a single molecule that sits at the intersection of energy, DNA integrity, brain performance, and longevity, it is nicotinamide adenine dinucleotide — NAD+. Once considered little more than a workhorse enzyme cofactor, NAD+ has emerged over the past two decades as a master regulator of cellular aging. And increasingly, high-performing executives, longevity-minded physicians, and precision health practitioners are turning not just to oral supplementation, but to injectable NAD+ delivery as a way to restore what decades of living progressively deplete.

This article breaks down the science. What is NAD+, how it differs from a peptide, what injectable administration actually does in the body, and — critically — what peer-reviewed research tells us about the benefits, the gaps, and the honest picture of where the science currently stands.

What Is NAD+?

NAD+ is a pyridine dinucleotide coenzyme found in every living cell of the human body. In its oxidized form (NAD+) and its reduced form (NADH), it functions as a critical electron carrier across the fundamental energy-producing pathways — glycolysis, the tricarboxylic acid (TCA) cycle, and mitochondrial oxidative phosphorylation. Without adequate NAD+, the mitochondria cannot efficiently generate adenosine triphosphate (ATP), the cellular currency that powers everything from muscle contraction to neuronal firing.

But NAD+ is far more than just a metabolic relay baton. It also functions as a required substrate — meaning it gets consumed — by three critically important classes of enzymes:

•       Sirtuins (SIRT1–7): NAD+-dependent deacylases that regulate gene expression, stress response pathways, mitochondrial biogenesis, and inflammation. SIRT1 activates PGC-1α, the master switch for mitochondrial production. SIRT3 activates antioxidant enzymes inside the mitochondrial matrix.

•       PARPs (Poly-ADP-Ribose Polymerases): Enzymes that detect and repair DNA strand breaks. PARP1 alone accounts for roughly 90% of all cellular DNA repair activity and consumes NAD+ in the process.

•       CD38/CD157 Ectoenzymes: Immune cell surface enzymes that regulate calcium signaling and immune activation — and are major consumers of NAD+ that increase with age and chronic low-grade inflammation.

The consequence of this tri-pathway demand is significant: as we age, NAD+ synthesis declines while enzymatic consumption increases. The result is a progressive depletion that multiple research groups have now quantified.

Research indicates that NAD+ levels decline approximately 40–60% between ages 40 and 70, driven by increased PARP activation, rising CD38 expression, and reduced NAMPT enzyme activity — the primary biosynthetic regulator.

NAD+ Is Not a Peptide — And the Distinction Matters

In the longevity and biohacking space, NAD+ is frequently discussed alongside peptide therapy, and the two are sometimes conflated. They are fundamentally different classes of molecules with different mechanisms of action, and understanding that difference is essential to appreciating what each one actually does.

What Is a Peptide?

Peptides are short chains of amino acids — typically 2 to 50 residues — joined by peptide bonds. They function primarily as signaling molecules. When administered therapeutically, peptides work by binding to specific cell surface receptors and triggering downstream biological responses. They do not directly participate in energy metabolism or enzyme cofactor activity. Their power lies in their ability to modulate precise pathways: BPC-157 signals tissue healing, Thymosin Alpha-1 modulates immune function, CJC-1295 stimulates growth hormone release, and so on.

Peptides are made of amino acids. They are, in structural terms, a class of proteins — specifically small proteins. They are encoded in DNA, synthesized on ribosomes, and broken down back into amino acids when metabolized.

What Is NAD+?

NAD+, by contrast, is a nucleotide-based coenzyme — a molecule composed of two nucleotides (nicotinamide mononucleotide and adenosine monophosphate) joined by a phosphodiester bond. It is not a signaling molecule in the receptor-binding sense. It does not bind to cell surface receptors to trigger a cascade. Instead, it operates inside the cell as a direct participant in enzymatic reactions — accepting and donating electrons, or being cleaved as a co-substrate by sirtuins and PARPs.

Think of peptides as the messaging system — they carry instructions that direct the body to perform specific functions. NAD+ is more like the power grid and repair infrastructure — the foundational substrate that those functions require to actually operate.

At a Glance: NAD+ vs. Peptides

•       Structure: Peptides = amino acid chains; NAD+ = nucleotide dinucleotide coenzyme

•       Mechanism: Peptides = receptor-mediated cell signaling; NAD+ = intracellular cofactor and enzymatic substrate

•       Primary Role: Peptides = targeted pathway modulation; NAD+ = energy metabolism, DNA repair, epigenetic regulation

•       Delivery Context: Peptides are often injectable for bioavailability; NAD+ is injectable to bypass GI conversion losses and achieve rapid systemic elevation

•       Combined Use: The two can be synergistic — NAD+ restores the energetic capacity that allows peptide-signaled repair and regeneration to actually occur

How Injectable NAD+ Works in the Body

NAD+ can be delivered orally — typically through precursor molecules such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), which the body must first convert into NAD+ — or it can be delivered directly into systemic circulation via intravenous (IV) infusion, intramuscular (IM) injection, or subcutaneous (SubQ) injection. The injectable route bypasses the gastrointestinal conversion process entirely.

The Oral Conversion Problem

When you take oral NAD+ precursors, the molecule does not simply absorb and distribute intact. NR and NMN must undergo enzymatic conversion steps through the salvage pathway before reaching intracellular NAD+ pools. These conversions are subject to digestive degradation, variable absorption efficiency, and saturation of the rate-limiting enzyme NAMPT. Oral supplementation has demonstrated significant blood-level increases — a landmark 2018 human randomized controlled trial published in Nature Communications showed that NR supplementation increased whole-blood NAD+ levels approximately 2.7-fold at doses of 1,000 mg/day — but cellular uptake in specific tissues, especially the brain, remains less predictable.

Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286.

The Injectable Advantage

Injectable NAD+ — whether delivered intravenously or subcutaneously — achieves measurable systemic plasma elevation without relying on the GI conversion cascade. A key investigative study published in Frontiers in Aging Neuroscience (PMC6751327) that tracked plasma and urinary NAD+ metabolites during a 6-hour intravenous NAD+ infusion found that infused NAD+ is rapidly taken up from plasma — completely removed within the first two hours — with metabolites detected consistent with NAD+ glycohydrolase activity, confirming active cellular processing rather than passive accumulation.

Braidy N, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Front Aging Neurosci. 2019;11:257. PMID: 31572155.

Subcutaneous injection offers a slower, more sustained release profile compared to IV infusion, with the adipose tissue layer acting as a controlled-release depot. This makes SubQ NAD+ suitable for outpatient or at-home protocols managed under physician oversight. Clinical protocols typically begin at 50 mg SubQ weekly, titrating to 100 mg based on tolerance, with the compound administered at standard insulin-depth sites: abdomen, outer upper arm, or anterior thigh with site rotation to prevent tissue irritation.

Injectable NAD+ bypasses the GI conversion process, achieving direct systemic plasma elevation and rapid cellular uptake — making it a mechanistically distinct and potentially more efficient delivery strategy compared to oral precursors alone.

What the Peer-Reviewed Research Shows

The science on NAD+ supplementation — across oral and injectable modalities — has advanced substantially over the past decade. Here is an honest, research-grounded summary of what the evidence currently supports.

1. NAD+ Restoration Is Measurably Achievable

Multiple randomized controlled trials have now confirmed that NAD+ supplementation — both oral precursors and direct administration — significantly elevates blood and tissue NAD+ levels in humans. A 2024 systematic review published in the American Journal of Physiology – Endocrinology and Metabolism (Gindri et al.) analyzed ten randomized clinical trials across PubMed, MEDLINE, Embase, Cochrane, and Web of Science and confirmed that NAD+ and NADH supplementation are both safe and effective at raising circulating NAD+ levels, with a favorable side effect profile compared to placebo.

Gindri IM, Ferrari G, Pinto LPS, et al. Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review. Am J Physiol Endocrinol Metab. 2024;326(4):E417–E427. doi:10.1152/ajpendo.00242.2023.

2. Mitochondrial Function and Energy Metabolism

NAD+'s role as an obligate electron carrier in mitochondrial oxidative phosphorylation is well-established. The clinical corollary — that restoring NAD+ supports mitochondrial efficiency — has been demonstrated in multiple human studies. A 2019 Cell Reports study by Elhassan et al. showed that nicotinamide riboside supplementation in aged skeletal muscle augmented the NAD+ metabolome and induced both transcriptomic changes and anti-inflammatory gene signatures — providing direct human tissue evidence for NAD+'s metabolic effects beyond blood-level changes.

Elhassan YS, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-Inflammatory Signatures. Cell Rep. 2019;28(7):1717–1728.e6.

The downstream implications for high performers are significant: NAD+-dependent sirtuin activity — specifically SIRT1's activation of PGC-1α and SIRT3's mitochondrial enzyme activation — represents a documented pathway by which NAD+ repletion supports mitochondrial biogenesis, metabolic homeostasis, and cellular stress resistance.

Imai S, Guarente L. NAD+ and Sirtuins in Aging and Disease. Trends Cell Biol. 2014;24(8):464–471. PMC4112140.

3. DNA Repair and Genomic Integrity

The relationship between NAD+, PARP1, and DNA repair is one of the most mechanistically well-characterized links in aging biology. As DNA damage accumulates with age, PARP1 activation escalates to manage repair — consuming increasing quantities of NAD+ and creating a potentially self-reinforcing depletion cycle. Multiple PMC-indexed studies have demonstrated that this NAD+ depletion loop is associated with reduced genomic stability, and that restoring NAD+ availability supports more efficient PARP-mediated repair capacity.

A 2020 benefit/risk analysis published in Experimental Gerontology (Braidy and Liu) concluded that NAD+ therapy in age-related degenerative disorders holds significant promise specifically through this DNA-repair axis, noting that oxidative stress-induced PARP activation and the resulting NAD+ drain is a measurable contributor to the neurological dysfunction seen in aging and neurodegenerative disease.

Braidy N, Liu Y. NAD+ therapy in age-related degenerative disorders: a benefit/risk analysis. Exp Gerontol. 2020;132:110831.

4. Neuroprotection and Cognitive Function

The brain is particularly vulnerable to NAD+ depletion given its high metabolic demands and sensitivity to mitochondrial dysfunction. Research has consistently linked NAD+ decline to neurodegenerative pathology. A 2022 double-blind, randomized, placebo-controlled trial published in Cell Metabolism (the NADPARK study by Brakedal et al.) demonstrated that nicotinamide riboside supplementation in Parkinson's disease patients measurably raised brain NAD+ levels and was associated with clinical improvements and markers of mitochondrial health — a landmark result for translational NAD+ research in neurodegeneration.

Brakedal B, Dölle C, Riemer F, et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab. 2022;34(3):396–407.e6.

A 2025 randomized controlled trial published in eClinicalMedicine (The Lancet) examined the effect of NAD+ restoration via nicotinamide riboside in long-COVID patients — a population with documented NAD+ metabolomic disruption — and found significant improvements in fatigue severity scores and multiple cognitive metrics over 10–20 weeks of supplementation.

Isman A, et al. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. eClinicalMedicine. 2025. PMID: NCT04809974.

5. Inflammation and Immune Modulation

Chronic low-grade inflammation — the "inflammaging" phenotype — is both a driver of NAD+ depletion (via CD38 upregulation) and a downstream consequence of it (via sirtuin impairment and NF-κB dysregulation). A 2022 study by Wu et al. published in the Journal of Clinical Investigation demonstrated that boosting NAD+ blunts toll-like receptor-4-induced type-I interferon production in both control and systemic lupus monocytes — providing direct human immune cell evidence that NAD+ elevation has measurable anti-inflammatory effects.

Wu J, Singh K, Lin A, et al. Boosting NAD+ blunts toll-like receptor-4 induced type-I interferon in control and systemic lupus erythematosus monocytes. J Clin Invest. 2022;132(11):e139828.

6. Addiction, Mood, and Psychiatric Burden

One of the more established clinical applications for intravenous NAD+ — with a longer clinical history — is its use in substance use disorder and withdrawal management. A 2022 observational study (Badgaiyan et al.) of 50 patients receiving NAD+ IV infusions found statistically significant reductions in craving scores, anxiety, and depressive symptoms across all three measures in patients with substance use disorder. This application has been used clinically for decades and represents one of the most data-supported use cases for the injectable route specifically.

Badgaiyan RD, Blum K, Han D, et al. Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequelae in Substance Use Disorder. Curr Psychopharmacol. 2022. doi:10.2174/2666082218666220527114427.

An Honest Assessment: What the Research Does and Doesn't Confirm

Bio Precision Aging is committed to evidence-based precision, not hype. The following is an accurate summary of the current state of the science.

What the evidence supports:

•       NAD+ levels reliably increase with supplementation — both oral precursors and direct administration — with injectable routes achieving faster systemic elevation

•       Sirtuin activation, PARP-mediated DNA repair signaling, and mitochondrial function improvements are mechanistically well-characterized in both animal models and human tissue studies

•       A favorable safety profile at tested doses, with mild transient side effects (nausea, flushing, injection site discomfort) in a minority of users and no serious adverse events reported in systematic review data

Where evidence is still evolving:

•       Direct injectable NAD+ (SubQ/IM) has fewer dedicated human RCTs than oral NR/NMN — most injectable-specific data comes from IV studies and clinical observation

•       Long-term outcome data on mortality, disease prevention, and healthspan extension in humans does not yet exist — the most compelling longevity data remains in animal models

•       Optimal dosing, administration frequency, and patient selection criteria for injectable formats are not yet standardized by clinical guidelines

•       A theoretical concern exists that NAD+ could support energy metabolism in existing cancer cells — though no clinical evidence of harm has been demonstrated in healthy adult populations at tested doses

The research base for NAD+ is robust at the mechanistic and early clinical level. The honest gap is in long-duration, large-scale human trials that directly compare injectable to oral routes. That research is actively underway.

Practical Considerations for the High-Performing Executive

If you are evaluating injectable NAD+ as part of a precision longevity protocol, here is what the evidence supports as best practice:

•       Source matters: Injectable NAD+ should come from an FDA-registered 503B compounding pharmacy or equivalent validated sterile production facility. Sterility is non-negotiable.

•       Physician oversight is required: SubQ injection protocols are typically initiated at 50 mg weekly and titrated to 100 mg based on tolerance under physician guidance.

•       Baseline testing is valuable: NAD+ levels can be measured via whole-blood assay. Knowing your baseline — and tracking change — is consistent with the precision health philosophy.

•       Stack strategically: NAD+ and peptide therapies address complementary mechanisms. NAD+ restores the energetic substrate that allows peptide-triggered repair and regeneration to function optimally. Neither replaces the other.

•       Injectable IV vs. SubQ: IV infusion provides the most rapid and complete systemic elevation. SubQ offers a more practical, sustained-release alternative for ongoing maintenance without clinical infusion infrastructure.

The Bottom Line

NAD+ is not a supplement trend. It is a foundational coenzyme at the center of how cells produce energy, repair their DNA, regulate inflammation, and modulate the epigenetic machinery that controls aging. The peer-reviewed evidence base — spanning sirtuins, PARP biology, mitochondrial function, neurodegeneration, and metabolic health — is substantial and growing.

Injectable NAD+ delivery — whether intravenous or subcutaneous — represents a mechanistically rational strategy for achieving more rapid and predictable systemic NAD+ elevation compared to oral precursors alone. The clinical data, while still maturing in terms of large-scale injectable-specific trials, is supported by a deep mechanistic literature and promising early human results.

For the executive who approaches their health the way they approach their highest-leverage decisions — with evidence, precision, and an aversion to leaving performance on the table — injectable NAD+ warrants serious, physician-guided consideration.

Key References (PubMed / PMC)

1. Gindri IM, et al. Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review. Am J Physiol Endocrinol Metab. 2024;326(4):E417–E427. PMID: 37971292.

2. Imai S, Guarente L. NAD+ and Sirtuins in Aging and Disease. Trends Cell Biol. 2014;24(8):464–471. PMC4112140.

3. Braidy N, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Front Aging Neurosci. 2019. PMC6751327.

4. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286.

5. Elhassan YS, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-Inflammatory Signatures. Cell Rep. 2019;28(7):1717–1728.e6.

6. Brakedal B, Dölle C, et al. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab. 2022;34(3):396–407.e6.

7. Wu J, Singh K, et al. Boosting NAD+ blunts TLR4-induced type-I interferon in SLE monocytes. J Clin Invest. 2022;132(11):e139828.

8. Braidy N, Liu Y. NAD+ therapy in age-related degenerative disorders: a benefit/risk analysis. Exp Gerontol. 2020;132:110831.

9. Camacho-Pereira J, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction. Cell Metab. 2016;23(6):1127–1139.

10. Radenkovic D, Reason, Verdin E. Clinical evidence for targeting NAD therapeutically. Pharmaceuticals (Basel). 2020;13(9):247. PMC7558103.

11. Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119–141.

12. Badgaiyan RD, Blum K, et al. NAD+ Infusions Significantly Attenuate Psychiatric Burden Sequelae in Substance Use Disorder. Curr Psychopharmacol. 2022. doi:10.2174/2666082218666220527114427.

Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. Injectable NAD+ is not FDA-approved as a therapeutic and is available as a compounded preparation. Always consult a qualified healthcare provider before beginning any injectable therapy or longevity protocol.